Skip to content

Clinical Efficacy of the Combined Effect of Oral Irrigator and Chemicals (0.075% CPC)

Antiplaque and Antigingivitis Efficacy of the Combined Effect of Oral Irrigator and Chemicals (0.075% CPC): a Randomized Clinical Trial with Experimental Gingivitis Model

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06607172
Acronym
WFPOC
Enrollment
30
Registered
2024-09-23
Start date
2024-09-30
Completion date
2024-10-22
Last updated
2024-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Plaque, Dental Plaque Induced Gingivitis, Dental Plaque and Gingivitis, Gingivitis

Keywords

dental hygiene products, gingivitis, dental plaque, oral irrigator

Brief summary

This is an experimental gingivitis clinical study to evaluate gum health efficacy from the combination effect of water flosser and chemistry (0.075% CPC) compared to water flosser and water and to no oral hygiene regimen with a 3-week follow-up. Thirty participants, aged between 18 and 70, will be enrolled.

Detailed description

This is an examiner blind, randomized controlled, parallel designed clinical study that aims to assess the gum health efficacy (antiplaque and antigingivitis) from the combination effect of water flosser and chemistry (0.075% CPC) compared to water flosser and water and to no oral hygiene in a 3-week experimental gingivitis. Thirty participants will be enrolled and allocated into 3 groups: group I - using a water flosser device and water each time; group II - using a water flosser device and dilutable chemistry product (0.075% CPC) after dilution each time (for groups I an II participants will use this regimen treatment twice daily, in the morning and evening, and no other oral hygiene will be allowed during the 21 days of follow-up); group III - negative control in which participants will abstain for any oral hygiene during the 21 days of follow-up. Gingival index measurements will be the primary efficacy variable after using the assigned regimen for 3 weeks for each subject. Subjects will under go baseline, 3 days, 1, 2 and 3 weeks visits. An Analysis of Covariance will be performed on the final or delta plaque scores using the baseline value as covariate. The F-test in this analysis will test the hypothesis that the waterflosser groups are equal in adjusted means.

Interventions

water flosser device

Cetylpyridinium 0.075%

Sponsors

Federal University of Pelotas
CollaboratorOTHER
Colgate Palmolive
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

This is a randomized, controlled, examiner blind, parallel-group clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Signed informed consent form; * Aged between 18 and 70; * Available for the three (3) week study duration; * Good general health for participation in the study, based on the opinion of the study investigator; * Must have at least 20 natural permanent teeth; * Teeth must meet the scoring entry criteria for dental plaque and gingivitis (gum inflammation) at the discretion of the study examiner.

Exclusion criteria

* Medical condition which requires premedication prior to dental visits/procedures; * Presence of fix/ removable prosthodontics dentures that may interfere with this study clinical examinations; * Advanced periodontal disease (gum disease) and/or treatment for periodontal disease (including surgery) within the past twelve months; * Five (5) or more decayed, untreated dental sites (cavities) and/or any dental condition requiring urgent dental care; * Abnormalities/diseases of the soft or hard oral tissues; * Orthodontic appliances/bands/lingual bars that interfere with any clinical assessment (plaque scoring) * Use of drugs that can affect salivary flow; * Use of antibiotics three (3) months prior to study entry and/or during participation in this study; * Use of any over the counter medications other than analgesics that could interfere with the study at PI discretion; * Self-reported pregnancy and/or breastfeeding; * Current Participation in another clinical study or during the month prior to this clinical study entry; * Known allergies and/or reactions to common dentifrice ingredients; * Medical condition which prohibits not eating/drinking or chewing gum for four (4) hours prior to your scheduled visits; * Immunocompromised conditions (AIDS, immunosuppressive drug therapy); * Infectious disease and/or other blood borne diseases (Hepatitis series, HIV, tuberculosis).

Design outcomes

Primary

MeasureTime frameDescription
Löe-Silness Gingival Index3 weeksA Löe-Silness Gingival Index score from 0 to 3 (0 = absence of inflammation and 3 = severe inflammation) will be assigned by the examining dentist to all scorable surfaces of the maxillary and mandibular teeth (6 sites/tooth) using a dental light and dental mirror. A whole mouth mean score for each subject will be determined by adding the values given by the examining dentist to each scorable surface and dividing that number by the total number of surfaces scored.

Secondary

MeasureTime frameDescription
Navy Plaque Index, Rustogi Modification3 weeksThe dentition will be disclosed with disclosing solution and plaque scored according to the Refined Navy Plaque Index. This index includes nine surfaces (marked A-I) examined for plaque after staining. Surfaces A, B, C denote the gingival margin surfaces, surfaces D and F the proximal surfaces. The total plaque score range is 0-9, the range for the gingival margin area is 0-3 and for the proximal area 0-2.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026